Details of the Drug
General Information of Drug (ID: DM2H9ND)
Drug Name |
5-(3-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
3-(5-Mercapto-[1,3,4]oxadiazol-2-yl)-phenol; 3-(5-mercapto-1,3,4-oxadiazol-2-yl)phenol; 299465-12-6; 3-(5-sulfanyl-1,3,4-oxadiazol-2-yl)phenol; CHEMBL595356; 3-(5-Mercapto-1,3,4-Oxadiazol-2-Yl)-Phenol; AO-365/08835025; 5-(3-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione; 5-[3-Hydroxyphenyl]-1,3,4-oxadiazole-2(3H)-thione; NSC524085; AC1LF1GV; Oprea1_836042; CTK8F4715; CTK8A0072; MolPort-000-932-334; ZX-AN016552; ZINC1605604; BB_SC-06098; CCG-15357; STK506749; FCH842308; BDBM50320729; BBL000571; AKOS000564154; FCH2245445; NSC-524085
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 194.21 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.7 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||